drugset / Trial / NCT02141217

AUGMENTIN™ in Dental Infections

NCT02141217

Phase 4 Completed 472 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindTreatment

Summary

In clinical practice, amoxicillin + clavulanic acid is widely used in the treatment of odontogenic infection. Therefore, this study is designed to generate data to support its use by demonstrating efficacy, safety and tolerability in comparison with clindamycin in subjects with acute odontogenic infections with or without abscess. This will be a two-arm, parallel, comparative, observer blind, randomised study to assess efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) in comparison with clindamycin (150mg) administered for 5-7 days in subjects with acute odontogenic infections with or without abscess. The study will be performed in adult subjects both male and female ≥18 years of age who present with acute odontogenic infections. A total of 472 subjects will be randomized in 1:1 ratio, i.e. 236 subjects in each treatment arm. The treatment duration of the study will be at least 5 days or maximum 7 days depending upon the treatment response. Subjects will be assessed on Day 5 and if Investigator feels the need of continuing the treatment at Day 5 then treatment will be continued till Day 7. For subjects who do not show treatment response on Day 5, assessments will be performed on Day 7.

Timeline

Start
2013-03-21
Primary completion
2013-12-28
Completion
2013-12-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 875 mg Oral
Comparator Clindamycin Unknown 150 mg Oral
Comparator clavulanic acid Small molecule 125 mg Oral

Indications